{"url_path":"/sec/vrtx/8-k/2026-05-13/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000204-index.html","accession_number":"0000875320-26-000204","cik":"0000875320","ticker":"VRTX","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","edgar_url":"https://www.sec.gov/Archives/edgar/data/875320/0000875320-26-000204-index.html","primary_entity_key":"0000875320","primary_entity_name":"VERTEX PHARMACEUTICALS INC / MA"},"word_count":274,"has_tables":true,"body_markdown":"Item 5.07  Submission of Matters to a Vote of Security Holders\n\nThe Annual Meeting was held on May 13, 2026. Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting:\n\nProposal No. 1: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider and Nancy Thornberry to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2027:\n\nForAgainstAbstainNon-Votes\n\nSangeeta Bhatia221,280,1731,624,14193,32210,337,217\n\nLloyd Carney213,048,5509,855,36993,71710,337,217\n\nAlan Garber219,396,4523,506,60494,58010,337,217\n\nReshma Kewalramani221,911,160999,30687,17010,337,217\n\nMichel Lagarde220,336,3432,566,48594,80810,337,217\n\nJeffrey Leiden220,333,7632,576,63887,23510,337,217\n\nDiana McKenzie221,316,5901,590,04790,99910,337,217\n\nBruce Sachs209,717,81513,186,26593,55610,337,217\n\nJennifer Schneider221,301,6701,602,68693,28010,337,217\n\nNancy Thornberry220,320,9922,583,89592,74910,337,217\n\nProposal No. 2: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026:\n\nForAgainstAbstainNon-Votes\n\n223,514,0709,597,395223,3880\n\nProposal No. 3: Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the Company's named executive officers:\n\nForAgainstAbstainNon-Votes\n\n207,918,84314,522,776556,01710,337,217\n\nProposal No. 4: Based upon the following votes, the shareholders approved the Company's 2026 Stock and Option Plan.\n\nForAgainstAbstainNon-Votes\n\n216,097,2686,523,460376,90810,337,217\n\nProposal No. 5: Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by written consent:\n\nForAgainstAbstainNon-Votes\n\n126,892,69695,756,148348,79210,337,217\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nVERTEX PHARMACEUTICALS INCORPORATED\n\n(Registrant)\n\nDate: May 13, 2026\n/s/ Joy Liu\n\nJoy Liu\n\nExecutive Vice President, Chief Legal Officer"}